<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996732</url>
  </required_header>
  <id_info>
    <org_study_id>YF-2021-01</org_study_id>
    <nct_id>NCT04996732</nct_id>
  </id_info>
  <brief_title>Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry</brief_title>
  <official_title>Studies on Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Fudan University Shanghai Cancer Center Registry（FUCaRe）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Real-world studies on long-term prognosis in patients who underwent anti-tumor treatments&#xD;
      during hospitalization from a hospital-based cancer registry in china.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center continuous enrollment cohort study. The overall survival and&#xD;
      disease-free survival of patients with malignant tumors in the target tumor hospital&#xD;
      undergoing surgery, radiotherapy, chemotherapy, and immunotherapy were observed. Follow-up&#xD;
      methods include medical records review, telephone call interview, and data linkage to the&#xD;
      related provincial death certificate registries. This study will provide real world data-sets&#xD;
      for researches on long-term survival and prognosis of cancer patients, and expend exploration&#xD;
      on the cancer survival determinants both from clinical and social-economic prospective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2041</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2040</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>15 years</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>15 years</time_frame>
    <description>the time from treatment to recurrence of cancer, second primary cancer or death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500000</enrollment>
  <condition>Neoplasms</condition>
  <condition>Survival</condition>
  <condition>Surgery</condition>
  <condition>Radiotherapy</condition>
  <condition>Drug Therapy</condition>
  <arm_group>
    <arm_group_label>All Cancers</arm_group_label>
    <description>subgroups according to cancer sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hospitalization</intervention_name>
    <description>Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization</description>
    <arm_group_label>All Cancers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who completed tumor treatment (including surgery, radiotherapy, chemotherapy,&#xD;
        immunotherapy, etc.) due to malignant tumors based on preoperative or intraoperative&#xD;
        evaluation in Fudan University Shanghai Cancer Center during the study period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who completed tumor treatment (including surgery, radiotherapy,&#xD;
             chemotherapy, immunotherapy, etc.) due to malignant tumors based on preoperative or&#xD;
             intraoperative evaluation in Fudan University Shanghai Cancer Center during the study&#xD;
             period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have not been treated during hospitalization;&#xD;
&#xD;
          -  Patients with non-malignant tumors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Zheng, Dr.</last_name>
    <phone>+8618121299522</phone>
    <email>zhengying@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Zheng, Dr.</last_name>
      <phone>+8618121299522</phone>
      <email>zhengying@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ying Zheng</investigator_full_name>
    <investigator_title>Director of Cancer Prevention Department, Fudan University Shanghai Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Survivorship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

